Working… Menu

Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03470350
Recruitment Status : Withdrawn (No study drug available. Same concept with new study drug will be explored in M19TGA study)
First Posted : March 19, 2018
Last Update Posted : July 24, 2019
Vall d'Hebron Institute of Oncology
European Organisation for Research and Treatment of Cancer - EORTC
Azienda Ospedaliera Niguarda Cà Granda
Fundación para la Investigación del Hospital Clínico de Valencia
University of Campania "Luigi Vanvitelli"
University of Turin, Italy
Eli Lilly and Company
Catalan Institute of Health
Universitaire Ziekenhuizen Leuven
Information provided by (Responsible Party):
The Netherlands Cancer Institute

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : June 1, 2020
Estimated Study Completion Date : June 1, 2020